For a microbiologist trekking through a remote rainforest or sampling the depths of a coastal estuary, the primary focus is usually the discovery: a rare microbe that could lead to a new antibiotic or a protein that helps plants survive extreme drought. But in the modern era of international research, the science is only half the battle. The other half is a complex, often opaque web of international law that determines whether that research is a legal breakthrough or a regulatory nightmare.
More than a decade after the Nagoya Protocol became law, a significant portion of the global scientific community remains in the dark about how to actually follow it. The treaty, designed to ensure that the benefits arising from the use of genetic resources are shared fairly and equitably with the countries of origin, was intended to end the era of “biopiracy.” Instead, for many researchers, it has created a climate of legal uncertainty that can stall publications, block the sharing of samples, and, in extreme cases, render their life’s work illegal.
Recognizing this gap, an international coalition of microbiologists and legal experts has released a comprehensive new guide to navigate these waters. Published in Sustainable Microbiology, the paper—titled “How to do the Nagoya Protocol: common misconceptions, challenges and best practices for access and benefit-sharing compliance”—serves as a practical manual for scientists who find the official legal texts incomprehensible.
The effort was led by the Leibniz Institute DSMZ and involved a massive collaboration across Horizon Europe consortia, including the Microbiome Biobanking Enabler (MICROBE) and the German Nagoya Protocol HuB. By bringing together voices from culture collections, universities, and research institutes, the team aimed to move the conversation from abstract legal theory to “policy in practice.”
The end of ‘helicopter science’
At the heart of the Nagoya Protocol is a push against what is colloquially known as “helicopter science.” This describes a practice where researchers from wealthy nations “drop in” to a biodiversity-rich country, collect samples, fly back to their home labs to conduct the analysis, and publish the results without ever involving or compensating the local scientists or the provider country.
While the scientific community has increasingly adopted “equity in science” as a moral best practice, the authors of the new guide warn that this is no longer just about ethics—it is about binding international law. Access and Benefit-Sharing (ABS) regulations are now integrated into the national laws of many countries. If a researcher fails to obtain the correct permits or ignores the benefit-sharing requirements, they aren’t just committing a faux pas; they are potentially conducting illegal research.
The consequences of non-compliance are severe. Beyond the risk of legal fines, researchers face devastating reputational damage. Institutions can be blacklisted, and journals may refuse to publish findings if the provenance of the genetic material cannot be legally verified. For many, the fear of these penalties has led to “defensive science,” where researchers avoid sampling in certain regions entirely to avoid the bureaucratic headache.
A roadmap through the bureaucracy
The new guidance attempts to replace this fear with a structured workflow. The team developed a five-step compliance framework designed to be integrated into the very beginning of a project’s design, rather than treated as an afterthought. The core philosophy is that ABS compliance is scalable and achievable if it is anticipated early.
According to the researchers, the “critical success factors” for a legal project include explicit consent for future uses of the samples, flexible permit conditions that allow for scientific evolution, and, most importantly, sustained engagement with in-country collaboration partners. The guide emphasizes that the most successful projects are those where the provider country is treated as a full partner in the research, rather than a mere source of raw materials.
To illustrate the difference between the old way of doing business and the Nagoya-compliant approach, the following table summarizes the shift in expectations:
| Research Element | Traditional Approach (Pre-Nagoya) | ABS-Compliant Approach |
|---|---|---|
| Sample Acquisition | Informal collection or simple permit | Prior Informed Consent (PIC) from national authority |
| Benefit Sharing | Publication credit (at best) | Mutually Agreed Terms (MAT) for financial/non-financial benefits |
| Partnership | Local guides or technicians | Co-authorship and capacity building with local scientists |
| Documentation | Lab notebooks and field logs | Internationally recognized certificates of compliance |
Persistent barriers and legal gray zones
Despite the new guidance, the authors acknowledge that the road to full compliance is still littered with obstacles. Ten years into the protocol, national procedures remain wildly inconsistent. A permit process in one country may be entirely digital and streamlined, while in another, it may require months of physical paperwork and ambiguous legal definitions.
One of the most pressing challenges involves human-associated microbes. The legal status of microbes found on or in humans—which may be collected in one country but belong to an individual—creates a “gray zone” of uncertainty. In some cases, this has forced researchers to renegotiate permits or seek renewed participant consent years after the samples were originally collected, threatening the continuity of long-term longitudinal studies.
The guide also highlights a systemic failure in scientific education. Many PhD students and early-career researchers enter the lab with deep technical knowledge but zero training in ABS law. The authors argue that Nagoya training must be integrated into life science curricula and biobank management to prevent a new generation of scientists from inadvertently breaking the law.
A call for global standardization
The burden of compliance does not fall solely on the scientist. The authors make a strong case for “provider countries” to modernize their approach. By promoting standardized model agreements and digital, multilingual due-diligence templates, governments can reduce the administrative burden on international teams without sacrificing their sovereignty over genetic resources.
the goal is to foster trust. When the rules are clear and the benefits are shared, the friction between conservation and discovery disappears. Robust ABS workflows do more than just protect a researcher’s reputation; they ensure that the pursuit of knowledge supports the conservation of the very biodiversity that makes that knowledge possible.
Disclaimer: This article is provided for informational purposes only and does not constitute legal advice. Researchers should consult with their institutional legal counsel or the ABS Focal Point of the relevant national authority to ensure compliance with international and local laws.
The next major milestone for the framework of the Nagoya Protocol will be the continued implementation of the Digital Sequence Information (DSI) agreement, as the global community works to determine how the protocol applies to genetic data shared digitally rather than as physical samples. This remains one of the most contested frontiers in international biological law.
Do you think the current legal requirements for genetic sharing hinder or help scientific progress? Share your thoughts in the comments or share this article with your colleagues.
